Radium-223 chloride

Drug Profile

Radium-223 chloride

Alternative Names: AC1O4D1M; Alpharadin; ATI-BC-1; BAY88-8223; Radium Ra 233 dichloride; Radium-223; Radium-223 dichloride; Xofigo

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Algeta
  • Developer Algeta; Bayer HealthCare; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone metastases
  • Phase I Osteosarcoma
  • Discontinued Cancer pain

Most Recent Events

  • 31 Oct 2016 Bayer completes a phase I trial in Bone metastases (Combination therapy) in USA, Israel and Finland (IV) (NCT02442063)
  • 13 Oct 2016 Bayer withdraws a phase II clinical trial for Bone metastases prior to enrolment in Canada (IV) (NCT02656563)
  • 10 Oct 2016 Bayer plans a phase Ib/II trial for Multiple Myeloma (Combination therapy, Second-line therapy or greater) in Australia, Belgium, Canada, Czech Republic, Germany, Greece, Israel, Italy, Japan, South Korea, New Zealand, Poland, Spain, Taiwan, USA (NCT02928029)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top